David A. Siegel Immatics N.V. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Immatics N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 59,800 shares of IMTX stock, worth $424,580. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,800
Previous 100,300
40.38%
Holding current value
$424,580
Previous $1.17 Million
41.46%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding IMTX
# of Institutions
101Shares Held
75.8MCall Options Held
238KPut Options Held
727K-
Rtw Investments, LP New York, NY10MShares$71 Million1.82% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$68.7 Million0.02% of portfolio
-
Perceptive Advisors LLC New York, NY8.09MShares$57.4 Million2.41% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.38MShares$52.4 Million0.05% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$45.7 Million0.79% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $541M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...